Diabetes drug could shield kidneys in rare disease
NCT ID NCT06090227
First seen Feb 03, 2026 · Last updated May 14, 2026 · Updated 14 times
Summary
This study tests whether the diabetes drug metformin can protect kidney cells in people with Focal Segmental Glomerulosclerosis (FSGS), a rare kidney disease. About 30 adults will receive either extended-release metformin or a placebo alongside their usual treatments for 6 months. The goal is to see if metformin reduces kidney cell injury and helps preserve kidney function.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOCAL SEGMENTAL GLOMERULOSCLEROSIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Mount Sinai Hospital
RECRUITINGNew York, New York, 10029, United States
Contact Email: •••••@•••••
Contact
Contact
Contact
-
Yale New Haven Hospital
RECRUITINGNew Haven, Connecticut, 06510, United States
Contact
Contact Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.